A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
NCT 06384352 Brief Summary This is a multicenter, open-label, Phase 1 study.…
Read more arrow_forwardNCT 06384352 Brief Summary This is a multicenter, open-label, Phase 1 study.…
Read more arrow_forwardACTRN 12620000592943 Brief Summary This purpose of this study is to determine…
Read more arrow_forwardACTRN 12623000307606 Brief Summary This study is investigating a new cancer treatment…
Read more arrow_forwardACTRN 12622001339741 Brief Summary This is a first in human study of…
Read more arrow_forwardACTRN 12618001074280 Brief Summary This study’s purpose is to facilitate and expedite…
Read more arrow_forwardNCT 05981703 Brief Summary This is an open-label, multicenter, and nonrandomized dose…
Read more arrow_forwardNCT 06929663 Brief Summary This is an first-in-human, Phase I clinical study…
Read more arrow_forwardNCT 06803680 Brief Summary The goal of this clinical trial is to…
Read more arrow_forwardNCT 05346484 Brief Summary This is an open-label, dose-escalation, multi-center phase I…
Read more arrow_forwardNCT 05279300 Brief Summary This is a first-in-human (FIH) study to evaluate…
Read more arrow_forward